American Research Corporation
American Research Corporation
San Antonio, Texas, United States7 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH) | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Recruiting | Phase 3 | 2026-10-08 | NCT07575399 | |
| Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bile duct disorder, biliary tract disorder, cholestasis, cirrhosis of liver, intrahepatic cholestasis, liver disorder, primary biliary cholangitis | Recruiting | Phase 3 | 2026-10-06 | NCT06051617 | |
| Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bile duct disorder, biliary tract disorder, cholestasis, cirrhosis of liver, intrahepatic cholestasis, liver disorder, primary biliary cholangitis | Active, not recruiting | Phase 3 | 2026-09-01 | NCT04526665 | |
| A Trial of Inebilizumab in Participants With Autoimmune Hepatitis | Digestive System Diseases, Hepatitis, Chronic, autoimmune disease, autoimmune hepatitis, hepatitis, immune system disorder, liver disorder | Not yet recruiting | Phase 3 | 2026-08-14 | NCT07598825 | |
| Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control Participants | Normal Hepatic Function; Severe Hepatic Impairment | Recruiting | Phase 1 | 2026-06-05 | NCT07250633 | |
| A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers. | Digestive System Diseases, Hepatic Insufficiency, liver disorder | Recruiting | Phase 1 | 2026-06-04 | NCT07401862 | |
| Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial | Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Nutritional and Metabolic Diseases, Wilson disease, basal ganglia disorder, brain disorder, central nervous system disorder, hereditary disease, inborn errors of metabolism, inborn metal metabolism disorder, inherited neurodegenerative disorder, liver disorder, metabolic disease, movement disorder, nervous system disorder, neurodegenerative disease | Active, not recruiting | Not stated | 2026-05-12 | NCT07226622 |